IDXX
IDEXX Laboratories, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
556.93
▲ 11.07 (2.03%)
MARKET · —
Price
Open
545.86
Prev close
545.86
Day high
557.66
Day low
545.62
Volume
472.69K
Market cap
$43.88B
P/E (TTM)
39.06
52W range
518.55 – 769.98
Trailing performance
Returnvs SPY
1W
+1.08%
+2.5%
1M
+3.26%
-0.5%
3M
+0.70%
-2.4%
6M
-12.39%
-23.5%
YTD
-17.68%
-30.0%
1Y
-12.96%
-33.0%
3Y
+11.49%
-62.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$43.88B
Enterprise value$44.77B
Revenue (TTM)$4.55B
Gross profit$2.84B
EBITDA$1.62B
Net income$1.14B
EPS (TTM)$14.26
Free cash flow$909.37M
Total cash$196.93M
Total debt$1.10B
Book value / share$20.45
Shares outstanding78.78M
Float78.50M
Short % of float2.80%
Dividend yield—
Beta (5Y)1.54
Valuation & profitability ratios
Trailing P/E39.06
Forward P/E33.27
PEG ratio3.44
Price / sales—
Price / book27.24
EV / revenue9.83
EV / EBITDA27.61
Gross margin62.45%
Operating margin34.98%
Profit margin25.03%
Return on equity74.21%
Return on assets27.08%
Debt / equity67.97
Current ratio1.17
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $4.30B | $3.90B | $3.66B | $3.37B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $1.06B | $887.87M | $845.04M | $679.09M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $1.06B | $887.87M | $845.04M | $679.09M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 3.93 | 4.27 | +8.5% |
| Mar 2026 | 3.41 | 3.47 | +1.7% |
| Dec 2025 | 2.94 | 3.08 | +4.8% |
| Sep 2025 | 3.15 | 3.40 | +8.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 3.71 | 12 | $1.19B | +7.8% |
| Next quarter | 3.37 | 11 | $1.17B | +7.7% |
| Current year | 14.83 | 13 | $4.72B | +9.8% |
| Next year | 16.74 | 13 | $5.14B | +8.8% |
Analyst targets & ownership
Mean target$698.92
High target$805.00
Low target$470.00
Implied upside25.50%
Analyst count13
ConsensusBUY
Strong buy / Buy4 / 4
Hold5
Sell / Strong sell0 / 1
Held by insiders0.22%
Held by institutions96.84%
Institutions holding1.86K
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+406
Net buying
Buy transactions
12
28.18K shares
Sell transactions
3
27.78K shares
Net transactions
+15
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
173.32K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 30, 26 | HOOLEY JOSEPH L. Director |
STOCK | 49 | $27.38K | Direct |
| Jun 1, 26 | FENNELL GEORGE Officer |
— | 639 | — | Direct |
| May 7, 26 | VANDEBROEK SOPHIE V Director |
— | 257 | — | Direct |
| May 7, 26 | KINGSLEY LAWRENCE D Director |
— | 339 | — | Direct |
| May 7, 26 | HOOLEY JOSEPH L. Director |
— | 158 | — | Direct |
| May 7, 26 | PEACOCK KAREN Director |
— | 101 | — | Direct |
| May 7, 26 | JUNIUS DANIEL M Director |
— | 257 | — | Direct |
| May 7, 26 | SZOSTAK MARGARET ANNE Director |
— | 257 | — | Direct |
| Apr 30, 26 | HOOLEY JOSEPH L. Director |
STOCK | 43 | $24.11K | Direct |
| Mar 3, 26 | HUNT NIMRATA K Officer |
SELL | 1.76K | $1.12M | Direct |
| Mar 3, 26 | UNDERBERG SHARON E General Counsel |
CONVERSION | 197 | $99.59K | Direct |
| Feb 27, 26 | MAZELSKY JONATHAN JAY Chief Executive Officer |
CONVERSION | 23.52K | $3.40M | Direct |
| Feb 26, 26 | HUNT NIMRATA K Officer |
SELL | 2.69K | $1.78M | Direct |
| Feb 26, 26 | MAZELSKY JONATHAN JAY Chief Executive Officer |
SELL | 23.33K | $15.34M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AYERS JONATHAN W |
Director | — | Stock Gift |
ERICKSON MICHAEL G |
Officer | 15.09K | Conversion of Exercise of derivative security |
FENNELL GEORGE |
Officer | 10.43K | Conversion of Exercise of derivative security |
HUNT NIMRATA K |
Officer | 18.30K | Sale |
KINGSLEY LAWRENCE D |
Director | 9.57K | Conversion of Exercise of derivative security |
LANE MICHAEL J |
Officer | 8.62K | Conversion of Exercise of derivative security |
MAZELSKY JONATHAN JAY |
Chief Executive Officer | 83.80K | Conversion of Exercise of derivative security |
MCKEON BRIAN P |
Chief Financial Officer | 49.60K | Conversion of Exercise of derivative security |
UNDERBERG SHARON E |
General Counsel | 7.14K | Conversion of Exercise of derivative security |
VANDEBROEK SOPHIE V |
Director | 9.08K | Conversion of Exercise of derivative security |
Moving averages & technicals
SMA 10
563.53
-1.17% from price
SMA 20
568.30
-2.00% from price
SMA 50
560.00
-0.55% from price
SMA 100
561.62
-0.84% from price
SMA 200
615.10
-9.46% from price
EMA 12
561.29
-0.78% from price
EMA 26
563.17
-1.11% from price
EMA 50
563.19
-1.11% from price
RSI (14)
47.5
Neutral
MACD (12,26,9)
-1.89
Hist -3.23
ATR (14)
21.12
3.79% of price
Realised vol 30D
31.5%
Annualised
Bollinger upper
598.58
20, 2σ
Bollinger lower
538.03
20, 2σ
50 / 200 cross
Death
560.00 vs 615.10
Trend bias
Below 200
-9.46%
Risk profile
Beta vs SPY
0.94
Less volatile than market
Correlation to SPY
0.38
Loosely linked
Realised vol 30D
31.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-31.3%
Peak to trough
Max drawdown 5Y
-52.8%
Peak to trough
ATR 14
21.12
3.79% of price
Beta (reported)
1.54
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
1.02
Put-heavy session
Put / call open interest
2.56
Positioning, not flow
Max pain
570.00
+2.3% from spot
ATM implied vol
33.1%
Nearest strike to spot
Skew (10% OTM)
-5.5%
Calls bid over puts
Call volume
44
Contracts, this expiry
Put volume
45
Contracts, this expiry
Heaviest call OI
650.00
31 contracts
Heaviest put OI
530.00
82 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
Zacks · 21h ago
Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding
Insider Monkey · 2d ago
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
Zacks · 2d ago
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
Zacks · 3d ago
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests
MarketBeat · 8d ago
Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?
Simply Wall St. · 9d ago
IDEXX (IDXX) Q2 2026 Earnings Call Transcript
Motley Fool · 11d ago
Sector Update: Healthcare Stocks Mixed Premarket Tuesday
MT Newswires · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.